{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:18:02Z","timestamp":1793395082962,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102445","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:30:12Z","timestamp":1758951012000},"page":"102445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5761-0186","authenticated-orcid":false,"given":"Asmaa","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Jabrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa M.","family":"AlEdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineddine","family":"Belabaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoria I. Essa","family":"Ghanm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa Ahmed","family":"Qutob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2025.102445_bib0001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.euo.2023.01.004","article-title":"Prognosis of primary papillary ta grade 3 bladder cancer in the non-muscle-invasivespectrum","volume":"6","author":"Beijert","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102445_bib0002","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1007\/s00345-021-03776-5","article-title":"Risk factors associated with positive surgical margins\u2019 location at radical cystectomy and their impact on bladder cancer survival","volume":"39","author":"Claps","year":"2021","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102445_bib0003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bju.15984","article-title":"Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy","volume":"132","author":"Claps","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102445_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nmograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102445_bib0007","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102445_bib0010","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical Bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Gu\u00e9rin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0011","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive blladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM evid"},{"issue":"3","key":"10.1016\/j.clgc.2025.102445_bib0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102445_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030694","article-title":"From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in Bacillus Calmette-Gu\u00e9rin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC)","volume":"14","author":"Deininger","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2025.102445_bib0014","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"Bladder Cancer BCG Study Group. Bacillus calmette\u2014Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2025.102445_bib0015","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical Nadofaragene Firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102445_bib0017","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.ju.0000100480.70769.0e","article-title":"Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy","volume":"171","author":"Schmidbauer","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102445_bib0018","unstructured":"LBA27 Phase 3 study of vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results | Request PDF. Accessed November 20, 2024. https:\/\/www.researchgate.net\/publication\/324205154_LBA27_PHASE_3_STUDY_OF_VICINIUM_IN_BCG-UNRESPONSIVE_NON-MUSCLE_INVASIVE_BLADDER_CANCER_INITIAL_RESULTS."},{"issue":"6","key":"10.1016\/j.clgc.2025.102445_bib0019","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102445_bib0021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102445_bib0022","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102445_bib0023","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/1078-0432.CCR-24-2812","article-title":"FDA approval summary: nadofaragene Firadenovec-vncg for Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"31","author":"Colbert","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102445_bib0024","unstructured":"Ongoing clinical trials and emerging agents in BCG-unresponsive NMIBC | Urology Times. Accessed September 3, 2025. https:\/\/www.urologytimes.com\/view\/ongoing-clinical-trials-and-emerging-agents-in-bcg-unresponsive-nmibc."},{"issue":"28","key":"10.1016\/j.clgc.2025.102445_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016426","article-title":"Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): a study based on 477 patients","volume":"98","author":"Lu","year":"2019","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:10:00Z","timestamp":1770671400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001454"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102445","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102445"}}